Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

NCT05186974 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05186974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05186974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 30, 2022
Completion date
March 31, 2027
Enrollment
193 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer